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Abstract: Despite the activity of standard chemotherapies in advanced breast cancer, disease 
progression remains inevitable. Most patients exposed to anthracyclines and taxanes develop 
resistance and a significant subset shows primary resistance. The increasing use of these agents 
as adjuvant therapy may result in more anthracycline- and taxane-resistant patients in the 
metastatic setting; few treatment options are available for patients with metastatic breast cancer 
(MBC) resistant to multiple chemotherapies. The heterogeneity of breast cancer represents 
another therapeutic challenge. Breast cancers may be classified as luminal, human epidermal 
growth factor 2 (HER2)-positive, or estrogen receptor-, progesterone receptor-, and human 
epidermal growth factor 2-negative (ER/PR/HER2-negative, triple negative). HER2-positive 
and ER/PR/HER2-negative tumors are associated with poor prognosis owing to aggressive 
disease and poor long-term response to therapy. The epothilone B analog ixabepilone has low 
susceptibility to multiple mechanisms of resistance and has demonstrated activity in patients 
with MBC resistant to anthracyclines, taxanes, and/or capecitabine. Ixabepilone is the first 
epothilone to be approved, as monotherapy or in combination with capecitabine, for treatment 
of resistant/refractory MBC or locally advanced breast cancer. Treatment with ixabepilone is 
an option for patients with ER/PR/HER2-negative or HER2-positive disease and/or primary 
resistance to taxanes.
Keywords: breast cancer, drug resistance, epothilone, HER2-positive, ixabepilone, ER/PR/
HER2-negative (triple negative)
Introduction
In the United States, an estimated 184,450 new cases of breast cancer will be diag-
nosed in 2008. Of these, almost 41,000 patients are expected to die from the disease.1 
Approximately 10% of patients have metastatic disease at the time of diagnosis, and 
20% to 85% of patients with early-stage breast cancer will eventually develop metastatic 
disease.2,3 Patients with metastatic breast cancer (MBC) treated with anthracycline- 
and/or taxane-based chemotherapy,3 have overall response rates (ORR) of 32% to 
68%.4,5 However, the benefits are relatively short-lived; median duration of response 
(DOR) ranges from 8 to 14 months,2 median survival is 2 to 3.5 years,2,3 and the 5-year 
survival rate is approximately 27%.6 Progression of MBC remains inevitable, and the 
majority of patients will eventually die of the disease.7
One significant factor that limits the efficacy of standard therapies for MBC is 
multidrug resistance (MDR), which can be either primary (preceding drug exposure) or 
acquired resistance (induced by treatment).4 Drug resistance is considered the cause of 
treatment failure in more than 90% of all patients with metastatic cancer.8 Mechanisms Drug Design, Development and Therapy 2009:3 164
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of MDR include overexpression of βIII-tubulin isotypes, and 
drug efflux transporters such as P-glycoprotein (P-gp) and 
multidrug resistance protein 1 (MRP1).9
Altered expression of βIII-tubulin in cancer cells is 
associated with increased resistance to microtubule inhibi-
tors such as the taxanes.10 Overexpression of βIII-tubulin 
alters microtubule assembly properties in vitro, resulting in 
a slower rate of polymerization and decreasing sensitivity 
to the microtubule-stabilizing taxanes.11 The decrease in 
sensitivity to paclitaxel in βIII-tubulin overexpressing cells 
appears associated with reduced binding to βIII-tubulin 
and/or the inability to induce conformational changes that 
suppress microtubule dynamics.12 Molecular modeling stud-
ies predict that paclitaxel binds to βIII-tubulin with reduced 
affinity versus βI-tubulin.13
Increased levels of βIII-tubulin have been observed in 
many tumor types, including breast, lung, ovarian, pancreatic, 
and prostate cancer cell lines.10 A univariate analysis in MBC 
showed a predictive correlation between βIII-tubulin expres-
sion and clinical response to paclitaxel-based chemother-
apy.14 Patients with lower levels of βIII-tubulin had improved 
tumor control following treatment with paclitaxel than those 
with high expression of βIII-tubulin. Increased βIII-tubulin 
expression has also been associated with poor prognosis 
as well as shorter progression-free and overall survival in 
patients with breast, lung, and ovarian cancers.10,14,15
Drug efflux transporters reduce intracellular concentra-
tions of hydrophobic drugs such as anthracyclines and tax-
anes by pumping them out of cells.9 Strong evidence of the 
role of these proteins in drug resistance has been obtained 
using tumor cell lines and animal models.9 However, evalu-
ation of their role in development of clinical drug resistance 
has been hampered by differences in methods used to assess 
their expression and by the heterogeneity of tumor specimens 
used for analysis.16 It is important to stress that analysis of a 
single mechanism does not fully capture the complex interac-
tions between multiple cellular pathways that are necessary to 
produce the MDR phenotype. Additionally, it is likely that a 
number of mechanisms with important roles in development 
of drug resistance remain to be elucidated. Nonetheless, sev-
eral lines of evidence strongly support an important role for 
drug efflux transporters in the development of clinical drug 
resistance. The proteins have been shown to be overexpressed 
in many human tumor types and their expression is associated 
with acquisition of drug resistance and with poor response to 
chemotherapy. Additionally, increased expression levels of 
P-gp and MRP-1 occur following exposure to chemotherapy 
in both normal and tumor cells.17,18
A meta-analysis of trials in breast cancer demonstrated 
that over 40% of untreated breast tumors express P-gp 
(41.2%) and MRP-1 (49%) as assessed by immunohisto-
chemistry (IHC).19 When assessed using polymerase chain 
reaction (PCR), expression of P-gp and MRP-1 was detected 
in 61% and 98% of untreated breast tumors, respectively.19 
Importantly, exposure to chemotherapy increased the expres-
sion of both proteins and P-gp expression was linked to a 
3-fold increase in the risk of treatment failure.20,21 The data 
also indicate a trend toward worse prognosis in breast cancer 
patients with early expression of MRP1.19
Most patients exposed to anthracyclines and taxanes 
develop resistance4 precluding long-term use of these agents 
and further limiting treatment options for this poor prognosis 
group. Furthermore, up to 55% of patients with MBC have 
primary taxane-resistance, defined as progressive disease as 
best response to taxane therapy.22,23 Treatment options for 
MBC patients following failure of anthracycline- and taxane-
based therapy include agents such as capecitabine, gem-
citabine, and vinorelbine. Response rates with gemcitabine 
and vinorelbine are 16% to 30%, and duration of response 
ranges from 4 to 7 months.24 Single-agent capecitabine, which 
is approved for use in MBC after prior anthracyclines and 
taxanes, demonstrated ORRs ranging from 9% to 28%, with 
median duration of response of 5.9 to 7.6 months.25–27 Efforts 
have focused on identifying new effective agents or combi-
nation regimens that provide benefit to patients with MBC 
resistant to multiple chemotherapies in terms of improved 
tumor control and survival.
Epothilones
Isolated from the myxobacterium Sorangium cellulosum, 
epothilones are a novel class of antineoplastic agents that 
promote polymerization of microtubules.28 Epothilones and 
taxanes occupy overlapping areas in the taxane-binding site 
on microtubules.29 However, the unique way in which the 
epothilones bind leads to differences in their mechanism of 
action compared with taxanes. Epothilones maintain activ-
ity against taxane-sensitive and -resistant cell lines, includ-
ing those overexpressing βIII-tubulin and P-gp. Molecular 
modeling studies predict distinct β-tubulin binding properties 
for epothilone A and paclitaxel. A similar binding affinity 
to βI and βIII-tubulin is predicted for epothilone A while 
paclitaxel is predicted to have higher binding affinity to βI-
tubulin.13 As poor substrates for drug efflux pumps, epothi-
lones are highly active against MDR cell lines, in vitro and 
in vivo.28,30 The naturally occurring epothilones patupilone 
(epothilone B, EPO906), and KOS862 (epothilone D), as well Drug Design, Development and Therapy 2009:3 165
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as the semisynthetic derivatives ixabepilone (BMS-247550, 
aza-epothilone), KOS-1584 (9,10,-didehydroepothilone), 
and ZK-epothilone (ZK-EPO, ZK-219477, sagopilone) 
have shown activity and distinct safety profiles in patients 
with advanced solid malignancies.31 Ixabepilone, the first 
approved drug in this class, is indicated as monotherapy 
or in combination with capecitabine for the treatment of 
patients with MBC resistant to anthracyclines, taxanes, and/or 
capecitabine. The other epothilones mentioned above are in 
various stages of clinical development, with the exception 
of KOS862, which has been discontinued in prostate and 
non–small-cell lung cancer.
Ixabepilone
Ixabepilone has low susceptibility to common mechanisms of 
resistance. For example, ixabepilone is active against Pat-21 
tumor xenografts.32 Pat-21 is a tumor model developed from 
a patient with MBC after failure of paclitaxel plus the MDR 
reversal drug dexverapamil. The patient had also received doxo-
rubicin, cyclophosphamide, methotrexate, and 5-fluorouracil. 
Pat-21 cells have high levels of βIII-tubulin but do not over-
express P-gp. The overexpression of βIII-tubulin in the Pat-21 
breast cancer model did not affect sensitivity to ixabepilone, 
whereas Pat-21 tumor xenografts were resistant to paclitaxel 
and docetaxel.32 In addition, ixabepilone is active in taxane-
resistant cell lines including the P-gp overexpressing HCT116/
VM46 (human colon carcinoma) and A2780Tax (human 
ovarian carcinoma) with mutated β-tubulin, and maintains 
activity in taxane-sensitive and -resistant tumor xenografts.30 In 
preclinical models, ixabepilone demonstrated synergistic activ-
ity when used in combination with capecitabine, cetuximab, 
trastuzumab, bevacizumab, or ipilimumab.33–36
Efficacy of ixabepilone in metastatic 
breast cancer
As a single agent or in combination with capecitabine, 
ixabepilone is efficacious across a range of patients with 
MBC including taxane-naïve, anthracycline-, taxane-, and/or 
capecitabine-resistant patients, as well as those with primary 
resistance to taxanes. Ixabepilone has proven efficacy in dif-
ferent breast cancer subtypes; patients with estrogen recep-
tor, progesterone receptor, and human epidermal growth 
factor receptor 2–negative (ER/PR/HER2-negative, triple 
negative) or HER2-positive disease have derived clinical 
benefit from ixabepilone treatment. Ixabepilone has been 
administered as first-, second or, third line in MBC as well 
as in the neoadjuvant setting, and has demonstrated efficacy 
across all lines of therapy evaluated.
Monotherapy
In a phase II study, Roché and colleagues administered 
ixabepilone at the recommended dose of 40 mg/m2 as an 
intravenous (iv) infusion over 3 hours every 3 weeks as 
first-line metastatic therapy to 65 MBC patients who had 
received anthracyclines in the adjuvant setting. Twenty-seven 
patients had a partial response (ORR 41.5%), median time 
to progression (TTP) was 4.8 months, and median overall 
survival (OS) was 22.0 months.37 The phase II study con-
ducted by Thomas and colleagues reported an ORR of 12% 
(6 partial responses) in 49 patients with taxane-resistant MBC 
who received ixabepilone. Median TTP was 2.2 months, 
with a median OS of 7.9 months.38 Perez and colleagues 
conducted a phase II study of ixabepilone in MBC patients 
with anthracycline-, taxane-, and capecitabine resistance. Of 
126 patients treated with ixabepilone, 113 were evaluable for 
response. The ORR was 11.5%, with 13 partial responses 
(Table 1). Median progression-free survival (PFS) was 3.1 
months, and median OS was 8.6 months.39
An alternative dose and schedule of ixabepilone has been 
evaluated in MBC. Denduluri and colleagues evaluated the 
activity of ixabepilone 6 mg/m2/d iv over 1 hour on days 1 
to 5 every 3 weeks in 23 taxane-naïve patients with MBC, 
12 of whom (52%) had received prior anthracyclines. The 
ORR was 57% (13 partial responses), and median TTP 
was 5.5 months. Seven of 12 (58%) patients who had prior 
anthracyclines had partial responses.40 In another phase 
II study, 37 taxane-refractory MBC patients received 
ixabepilone 6 mg/m2/d iv over 1 hour on days 1 to 5 every 
3 weeks. Ixabepilone treatment resulted in an ORR of 22%, 
with 1 complete response and 7 partial responses (Table 1), 
and a median TTP of 2.6 months.41
Combination therapy
Based on the single-agent activity and demonstrated synergy in 
preclinical models35 an ixabepilone plus capecitabine regimen 
was evaluated in a phase I/II study with anthracycline- and 
taxane-resistant MBC patients. The recommended dose 
for the combination regimen was ixabepilone 40 mg/m2 iv 
over 3 h every 3 weeks and oral capecitabine 2000 mg/m2 
administered in 2 divided doses daily on days 1 to 14 every 
3 weeks. Of 50 evaluable patients, 1 complete response and 
14 partial responses were observed (ORR 30%) and median 
PFS was 3.8 months.42 A large randomized phase III study 
compared the ixabepilone plus capecitabine combination with 
capecitabine monotherapy in 752 patients with anthracycline- 
and taxane-resistant MBC.43 Patients were randomly 
assigned to receive ixabepilone plus capecitabine (N = 375) Drug Design, Development and Therapy 2009:3 166
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or capecitabine alone (N = 377) (Table 2). Ixabepilone plus 
capecitabine treatment led to a 31% decrease in the risk of 
disease progression (hazard ratio [HR] 0.69; 95% confidence 
interval [CI], 0.58–0.83; p  0.0001), and a 39% increase in 
median PFS (5.7 months compared with 4.1 months in the 
capecitabine monotherapy arm).44 The combination regimen 
was superior to capecitabine, with ORRs of 35% vs 14% in 
the respective treatment arms.43 The overall survival data 
are expected in 2009.
Safety and tolerability  
of ixabepilone
Monotherapy
Ixabepilone has demonstrated a manageable safety profile in 
chemonaïve, and in mildly or heavily pretreated patients as a 
single agent. Neutropenia and peripheral sensory neuropathy 
were the most frequently noted grade 3/4 adverse events with 
the administration of ixabepilone 40 mg/m2 every 3 weeks; 
febrile neutropenia was uncommon (Table 3). Grade 3/4 
neutropenia reported with ixabepilone 40 mg/m2 Q3W 
monotherapy ranged from 53% to 58%, and was generally 
manageable.37–39 Febrile neutropenia occurred in 6% of 
patients in these trials (Table 1). At the alternate dosage 
(6 mg/m2/d iv over 1 hour on days 1 to 5 every 3 weeks), grade 
3/4 neutropenia occurred in 22% and 35% of patients.40,41 The 
incidence of grade 3/4 febrile neutropenia ranged from 0% and 
14%.40,41 Peripheral sensory neuropathy was primarily grade 
1/2, even in heavily pretreated patients. Grade 3/4 sensory 
neuropathy occurring in 12% to 20% of patients was cumula-
tive and mostly reversible, resolving to baseline or grade 1 
within a median of 5.4 weeks following dose adjustments 
or treatment delay.45 Discontinuation of ixabepilone is 
Table 1 Efficacy of ixabepilone monotherapy in metastatic breast cancer
Investigator Roché et al37 Thomas et al38 Perez et al39 Low et al41 Denduluri et al40
Patient population A-resistant T -resistant A-, T -, C-resistant T -resistant T -naïve
Patient number N = 65 N = 49 N = 113 N = 37 N = 23
Dosing schedule 40 mg/m2; 3-hour iv infusion; day 1; Q3w 6 mg/m2; 1-h iv infusion; days 1 to 5 Q3w
Median Orr (%)  
[95% Ci]
41.5  
[29.4 to 54.4]
12.2  
[4.7 to 26.5]
11.5  
[6.3 to 18.9]
22 [9.8 to 38.2] 57 [34.5 to 76.8]
Median PFS (mo)  
[95% Ci]
(TTP) 4.8  
[4.2 to 7.6]
(TTP) 2.2  
[1.4 to 3.2]
3.1  
[2.7 to 4.2]
2.6  
[Nr]
(TTP) 5.5  
[Nr]
Median OS (mo)  
[95% Ci]
22.0  
[15.6 to 27.0]
7.9  
[6.1 to 14.5]
8.6  
[6.9 to 11.1]
[Nr] [Nr]
Abbreviations: A, anthracycline; C, capecitabine; iv, intravenous; Nr, not reported; Orr, overall response rate; OS, overall survival; PFS, progression-free survival; T, taxane; 
TTP, time to progression.
Table 2 Efficacy of ixabepilone plus capecitabine in metastatic breast cancer
Investigator Bunnell et al42 Thomas et al43; Thomas44
Patient Population A- and T -resistant A- and T -resistant
Phase ii iii
Patient number N = 50 N = 375 N = 377
Dosing schedule ixabepilone 40 mg/m2; 3-hour iv 
infusion; d1 Q3w plus  
Capecitabine 2000 mg/m2,  
oral, d 1 to14 Q3w
ixabepilone 40 mg/m2; 3-hour iv  
infusion; d1 Q3w plus  
Capecitabine 2000 mg/m2,  
oral, d 1 to14 Q3w
Capecitabine 2500 mg/m2, oral,  
d 1 to 14 Q3w
Median Orr (%)  
[95% Ci]
30.0  
[18 to 45%]
34.7  
[29.9 to 39.7]
14.3  
[10.9 to 18.3]
Median PFS (mo)  
[95% Ci]
3.8  
[2.7 to 5.6]
5.7  
[4.8 to 6.7]
4.1  
[3.1 to 4.3]
Hazard ratio  
[95% Ci]
0.69  
[0.58 to 0.83]
p  0.0001 p-value
Abbreviations: A, anthracycline; iv, intravenous; Nr, not reported; Orr, overall response rate; OS, overall survival; PFS, progression-free survival; T, taxane.Drug Design, Development and Therapy 2009:3 167
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recommended in patients with grade 3 neuropathy 7 
days or any grade 4 neuropathy.46 A 20% dose reduction is 
recommended in patients with grade 2 neuropathy 7 days 
or grade 3 neuropathy 7 days.46 The trials of the lower 
ixabepilone dose (6 mg/m2/day iv over 1 hour on days 1 to 
5 every 3 weeks) reported fewer incidences of grade 3/4 
peripheral sensory neuropathy (3%) (Table 3).40,41 Grade 
3/4 peripheral motor neuropathy was noted in 5% of 
patients at standard ixabepilone dosing.37–39 Other grade 3/4 
adverse events noted with ixabepilone treatment include 
fatigue (6% to 27%), myalgia/arthralgia (3% to 13%), and 
diarrhea (1% to 11%).37–41
Combination therapy
Adverse events associated with the ixabepilone plus 
capecitabine combination were consistent with the safety 
profile of the individual agents (Table 3). Grade 3/4 
adverse events reported in patients receiving ixabepilone 
plus capecitabine included neutropenia (68%), leukopenia 
(57%), and peripheral sensory neuropathy (21%).43 There 
was an increased risk of severe neutropenia, febrile neutro-
penia, and neutropenia-related toxic death in the ixabepi-
lone plus capecitabine treatment arm versus capecitabine 
monotherapy. Grade 3/4 febrile neutropenia was 4.8% and 
0.5% in the combination and capecitabine monotherapy 
arms, respectively.43 Owing to the hepatic metabolism of 
ixabepilone, investigators noted a higher risk of toxicity 
in patients receiving Ixabepilone and capecitabine with 
moderate or severe hepatic impairment at baseline. Neutro-
penia-related deaths occurred in 7 of 353 patients (1.9%) 
with moderate (grade 0/1) baseline liver impairment, and 
in 5 of 16 patients (31%) with severe (grade  2) baseline 
hepatic dysfunction.43 Dose adjustments have been recom-
mended for patients with moderate or severe liver dysfunc-
tion receiving ixabepilone monotherapy.47 The ixabepilone 
plus capecitabine combination is contraindicated in patients 
with AST or ALT  2.5 × upper limit of normal (ULN) or 
bilirubin 1 × ULN.46 Conversely, patients with normal or 
mild hepatic impairment had prolongation of PFS by 2.0 
months compared to capecitabine alone (6.2 vs 4.2 months; 
HR, 0.73).43 Peripheral sensory neuropathy occurred in 
65% of patients in the ixabepilone plus capecitabine arm, 
and was generally mild to moderate (grade 1/2, 44%; grade 
3/4, 21%).43 Grade 3/4 peripheral sensory neuropathy was 
manageable with dose adjustments and reversible; 89% 
of patients had resolution to baseline or grade 1 within a 
median of 6.0 weeks.48 Rates of grade 3/4 hand-foot syn-
drome were nearly equivalent, 18% with ixabepilone plus 
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capecitabine and 17% with capecitabine monotherapy.43 In 
the phase III trial, 11% of patients in the ixabepilone plus 
capecitabine arm had grade 3/4 myalgia/arthralgia versus 
0.3% in the capecitabine monotherapy arm.43 Grade 3/4 
fatigue was experienced by 9% versus 3.3% of patients 
receiving ixabepilone plus capecitabine and capecitabine 
monotherapy, respectively. Grade 3/4 diarrhea was reported 
in 6% and 8.5% of patients in the respective arms.43
Efficacy of ixabepilone in specific 
MBC patient subpopulations
Approximately 10% to 25% of all breast cancer cases are 
ER/PR/HER2-negative49–52 and primary taxane resistance 
has been observed in up to 55% of breast cancer patients.22,23 
Patients who fall into these categories generally have a 
poorer prognosis and shorter survival compared with their 
counterparts.49,51 Effective treatment options are limited 
for the sizeable portion of breast cancer patients in these 
subpopulations largely affected by aggressive disease. 
Ixabepilone has demonstrated efficacy in patients with ER/
PR/HER2-negative or HER2-positive disease, as well as 
those with primary taxane resistance, and represents a novel 
therapeutic option for these populations (Tables 4 and 5).
Subgroup analyses of ER/PR/HER2-negative patients 
in 3 phase II trials evaluated the activity of ixabepilone in 
this poor prognosis population. Eleven of 65 patients in 
the trial conducted by Roché and colleagues had ER/PR/
HER2-negative disease. The response to ixabepilone mono-
therapy in this subpopulation was 55% with median PFS of 
4.6 months.53 Eighteen of 49 patients in the phase II trial 
by Thomas and colleagues were ER/PR/HER2-negative; 
following ixabepilone treatment, the ORR in these patients 
was 6% and median PFS was 1.6 months.53 The trial con-
ducted by Perez et al included 42 ER/PR/HER2-negative 
patients of the 126 enrolled. The ORR was 12%, and median 
PFS was 2.7 months. In the neoadjuvant setting, the ORR was 
64% and the pathologic complete response in breast (pCRB) 
was 26% in patients with ER/PR/HER2-negative disease 
receiving up to 4 cycles of ixabepilone 40 mg/m2 every 
3 weeks versus 18% in the overall patient population.53,54
Prospective analyses of specific patient subpopulations 
in the phase III trial of ixabepilone plus capecitabine versus 
capecitabine alone showed superiority of the combination 
regimen. In the ixabepilone plus capecitabine arm, 91 
patients (24%) were ER/PR/HER2-negative, 164 (44%) 
were ER-negative, 59 (16%) were HER2-positive, and 
150 (40%) had primary taxane resistance. Patients with 
ER/PR/HER2-negative disease had an ORR of 27% 
following treatment with the combination versus 9% with 
the capecitabine monotherapy.48 The ixabepilone plus 
capecitabine combination improved median PFS compared 
with capecitabine alone; 4.1 versus 2.1 months (HR = 0.68).48 
The ER-negative population also had improved median PFS; 
4.4 versus 2.8 months (HR = 0.65, p  0.0001). The ORRs 
were 30% and 10% for ER-negative patients in the com-
bination and capecitabine monotherapy arms, respectively 
(Table 5)55 Ixabepilone plus capecitabine improved median 
PFS in HER2-positive patients; 5.3 versus 4.1 months with 
capecitabine alone (HR = 0.69, p = 0.06). The ORRs were 
31% and 8% in the respective arms.56 Safety and tolerability 
of ixabepilone in the patient subpopulations were similar to 
the overall population.48,53,57
Subset analyses demonstrated efficacy of ixabepilone 
mono- or combination therapy in MBC patients with primary 
taxane resistance, defined as progressive disease as best 
response to prior taxanes. In the phase III study, patients in 
the ixabepilone plus capecitabine arm had a median PFS of 
5.6 months versus 4.9 months in the capecitabine arm; ORRs 
were 33% vs 13%, respectively.57 Similarly, in a phase II trial, 
ixabepilone was active as monotherapy in MBC patients with 
primary taxane resistance.39,57
Conclusions
Disease progression in MBC is common. The increasing use 
of anthracycline- and taxane-based regimens in the adjuvant 
setting and the development of resistance to these agents 
Table 4 ER/PR/HER2-negative metastatic breast cancer – efficacy of ixabepilone monotherapy
Investigator Roché et al37 Thomas et al38 Perez et al39
Patient population A-resistant T -resistant A-, T -, C-resistant
Number of er/Pr/Her2-negative patients N = 11 N = 18 N = 42
Median Orr (%) 55% 6% 12%
Median PFS (months) [95% Ci] 4.6 [2.8 to 9.3] 1.6 [1.3 to 2.3] 2.7 [1.5 to 5.9]
Notes: ixabepilone 40 mg/m2 administered once every 3 weeks.
Abbreviations: A, anthracycline; C, capecitabine; er, estrogen receptor; Her2, human epidermal growth factor 2; Nr, not reported; Orr, overall response 
rate; Pr, progesterone receptor; PFS, progression-free survival; T, taxane.Drug Design, Development and Therapy 2009:3 169
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limit their efficacy against metastatic disease. Few agents 
have demonstrated activity after failure of anthracyclines 
and taxanes and in most cases, with little effect on disease 
progression.
Higher response rates were observed in taxane naïve and/
or anthracycline pretreated patients receiving ixabepilone. 
Reduced response rates were observed in patients resistant to 
taxanes or anthracyclines, taxanes and capecitabine (Table 1). 
These data are consistent with previously observed reduc-
tion in therapeutic efficacy in patients who have developed 
resistance to one or more chemotherapeutic agents and/or 
with increasing lines of therapy.58 Nonetheless, consistent 
with the preclinical data, the results suggest that ixabepilone 
may overcome and/or circumvent at least some of the cel-
lular mechanisms that block taxane-, anthracycline- and/or 
capecitabine-induced cytotoxicity.
Overall, the clinical studies have demonstrated that 
ixabepilone:
•  Has low susceptibility to common mechanisms of drug 
resistance, such as βIII tubulin overexpression.
•  Is efficacious against anthracycline- and taxane-pretreated 
MBC.
•  Has a manageable safety profile.
•  Provides significant clinical benefit to patients with ER/
PR/HER2-negative and HER2-positive disease, and/or 
patients with primary resistance to taxanes.
Based on the data from the phase II and III trials in MBC, 
ixabepilone received approval from the United States Food 
and Drug Administration (FDA) for use in combination with 
capecitabine for the treatment of patients with MBC resistant 
to anthracyclines and taxanes, and as monotherapy for MBC 
patients resistant or refractory to anthracyclines, taxanes, and 
capecitabine. However, the European Medicines Agency 
(EMEA) Committee for Medicinal Products for Human Use 
(CHMP) did not approve marketing authorization for ixabepi-
lone citing concerns over treatment-related neuropathy.
A recently completed analysis of survival data from the 
2 large phase III ixabepilone trials in MBC demonstrated 
a trend towards increased OS that did not reach statistical 
significance.59 However, an OS benefit was reported in 
patients treated with ixabepilone following a pre-defined 
Cox Regression analysis with data adjusted according to 
prognostic factors.60
A number of ongoing trials are evaluating ixabepilone in 
combination with other chemotherapeutic and biologic agents 
for treatment of a variety of tumor types. A preliminary report 
indicates that ixabepilone in combination with epirubicin 
is active in patients with MBC.61 Additionally, an overall 
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response rate of 53.8% was reported for ixabepilone in 
combination with trastuzumab in patients with HER2-positive 
metastatic breast cancer.62 The results of additional trials 
examining ixabepilone combination therapy in patients with 
MBC are anticipated in 2009.
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